INCYTE CORPORATION
NASDAQ: INCY (Incyte Corporation)
Kemas kini terakhir: 2 jam lalu116.93
3.49 (3.08%)
| Penutupan Terdahulu | 113.44 |
| Buka | 113.93 |
| Jumlah Dagangan | 2,235,198 |
| Purata Dagangan (3B) | 1,650,083 |
| Modal Pasaran | 23,701,446,656 |
| Harga / Pendapatan (P/E TTM) | 14.90 |
| Harga / Pendapatan (P/E Ke hadapan) | 14.71 |
| Harga / Jualan (P/S) | 4.47 |
| Harga / Buku (P/B) | 4.05 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Oct 2026 |
| Margin Keuntungan | 0.48% |
| Margin Operasi (TTM) | 20.65% |
| EPS Cair (TTM) | 0.200 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 19.50% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -6.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.18% |
| Nisbah Semasa (MRQ) | 2.04 |
| Aliran Tunai Operasi (OCF TTM) | 382.59 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 618.05 M |
| Pulangan Atas Aset (ROA TTM) | 2.04% |
| Pulangan Atas Ekuiti (ROE TTM) | 0.47% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Incyte Corporation | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | -5.0 |
| Kesihatan Kewangan | NA |
| AI Insight | NA |
| Purata | 0.22 |
|
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 2.01% |
| % Dimiliki oleh Institusi | 100.65% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Baker Bros. Advisors Lp | 30 Jun 2026 | 30,762,330 |
| Lsv Asset Management | 30 Jun 2026 | 4,123,759 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CAGNONI PABLO J | - | 113.27 | -2,642 | -299,259 |
| Jumlah Keseluruhan Kuantiti Bersih | -2,642 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -299,259 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 113.27 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| CAGNONI PABLO J | Pegawai | 15 Oct 2026 | Jual (-) | 2,642 | 113.27 | 299,259 |
| CAGNONI PABLO J | Pegawai | 15 Oct 2026 | Pelaksanaan pilihan | 2,642 | - | - |
AI Analisis Teknikal
Buka tab Teknikal untuk menjana analisis terkini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |